Valley Preferred and the ABMS Offer MOC and PI-CME Credit for Health Care Achievements under COVID-19

Valley Preferred, the preferred provider organization affiliated with Lehigh Valley Health Network (LVHN), has introduced COVID-19 Healthcare Delivery and Transformation. As an American Board of Medical Specialties (ABMS) Portfolio Sponsor®, Valley Preferred has integrated this new project into its Maintenance of Certification (MOC) program.

The project’s premise is to document and maximize the contributions of health care workers during this unprecedented time. By attesting to their participation, allopathically boarded physicians and PAs will be awarded credit – ABMS MOC Improvement in Medical Practice (Part IV) or National Commission on Certification of Physician Assistants (NCCPA) PI-CME – for these accomplishments.

“All physicians and physician assistants became front line quality improvement practitioners during the pandemic because changes were constant,” says John Stoeckle, MD, who heads Valley Preferred’s MOC Portfolio Program™. “Everyone was already doing great work, so we saw this as a perfect opportunity. Clearly, it’s one of the best ways to recognize our professionals’ many outstanding contributions.”

COVID-19 Healthcare Delivery and Transformation is currently active among Valley Preferred’s members. The organization believes the initiative is an excellent model for health system leaders and providers to see work happening in real time versus education from vehicles such as learning modules.

An individual’s work can fall into one of four topic areas:

  • Increasing virtual visit workflows
  • Increasing COVID-19 testing
  • Safe and appropriate PPE acquisition and use
  • Safe/appropriate inpatient COVID-19 treatment

The COVID-19 project was developed and put into place quickly as a result of multidisciplinary teamwork. Support was received from every facet of LVHN and Valley Preferred, and from leadership through various other departments. The project’s end goal, in addition to assisting physicians and PAs with needed certifications, is, according to Dr. Stoeckle, “recognizing meaningful professional development and our development of a culture of quality improvement.”

“Valley Preferred is dedicated to creating value for its members first and foremost, whether that involves thinking about well-being, reducing administrative burdens, or working toward the optimal care of patients,” says Dr. Stoeckle. “Our organization saw this project as one that immediately aligns with our values, and took all the necessary steps to actualize it in a timely manner.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version